These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 35478222)

  • 21. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done.
    Schito M; Maeurer M; Kim P; Hanna D; Zumla A
    Clin Infect Dis; 2015 Oct; 61Suppl 3(Suppl 3):S95-101. PubMed ID: 26409286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the development of new tuberculosis drugs and treatment regimens.
    Zumla A; Nahid P; Cole ST
    Nat Rev Drug Discov; 2013 May; 12(5):388-404. PubMed ID: 23629506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
    Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
    Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Challenges and opportunities in developing novel drugs for TB.
    Kaneko T; Cooper C; Mdluli K
    Future Med Chem; 2011 Sep; 3(11):1373-400. PubMed ID: 21879843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Target Identification in Anti-Tuberculosis Drug Discovery.
    Capela R; Félix R; Clariano M; Nunes D; Perry MJ; Lopes F
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445660
    [No Abstract]   [Full Text] [Related]  

  • 27. Global tuberculosis drug development pipeline: the need and the reality.
    Ma Z; Lienhardt C; McIlleron H; Nunn AJ; Wang X
    Lancet; 2010 Jun; 375(9731):2100-9. PubMed ID: 20488518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advanced cellular systems to study tuberculosis treatment.
    Bielecka MK; Elkington P
    Curr Opin Pharmacol; 2018 Oct; 42():16-21. PubMed ID: 29990957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The challenge of new drug discovery for tuberculosis.
    Koul A; Arnoult E; Lounis N; Guillemont J; Andries K
    Nature; 2011 Jan; 469(7331):483-90. PubMed ID: 21270886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in the development of drugs for the treatment of tuberculosis.
    Shehzad A; Rehman G; Ul-Islam M; Khattak WA; Lee YS
    Braz J Infect Dis; 2013; 17(1):74-81. PubMed ID: 23287547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.
    Lee BY; Clemens DL; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    Nat Commun; 2017 Jan; 8():14183. PubMed ID: 28117835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights into TB physiology suggest untapped therapeutic opportunities.
    Baer CE; Rubin EJ; Sassetti CM
    Immunol Rev; 2015 Mar; 264(1):327-43. PubMed ID: 25703570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introduction: Novel insights into TB research and drug discovery.
    Grüber G
    Prog Biophys Mol Biol; 2020 May; 152():2-5. PubMed ID: 32087187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TB drug development: immunology at the table.
    Nathan C; Barry CE
    Immunol Rev; 2015 Mar; 264(1):308-18. PubMed ID: 25703568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Public-private partnership tackles TB challenges in parallel.
    Webb S
    Nat Rev Drug Discov; 2009 Aug; 8(8):599-600. PubMed ID: 19644463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets.
    Alsayed SSR; Gunosewoyo H
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982277
    [No Abstract]   [Full Text] [Related]  

  • 37. The Changing Paradigm of Drug-Resistant Tuberculosis Treatment: Successes, Pitfalls, and Future Perspectives.
    Dookie N; Ngema SL; Perumal R; Naicker N; Padayatchi N; Naidoo K
    Clin Microbiol Rev; 2022 Dec; 35(4):e0018019. PubMed ID: 36200885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials.
    Ahsan MJ; Ansari MY; Yasmin S; Jadav SS; Kumar P; Garg SK; Aseri A; Khalilullah H
    Infect Disord Drug Targets; 2015; 15(1):32-41. PubMed ID: 25246035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis.
    Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in the research of heterocyclic compounds as antitubercular agents.
    Yan M; Ma S
    ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.